CHRS Coherus Oncology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1512762 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY44.4%
TTM net income YoY-187.7%
TTM EPS YoY-175.2%
Revenue 3-yr CAGR-36.7%
Net income 3-yr CAGR—
Margins
Gross margin69.8%
Operating margin-275.9%
Net margin-253.4%
FCF margin—
EBITDA margin-274.3%
Returns
ROE-240.5%
ROA-39.5%
ROIC (approx.)—
Asset turnover0.16x
Leverage & solvency
Liabilities / assets85.2%
Debt / equity0.00x
Current ratio1.51x
Interest coverage-15.52x
Cash quality & payout
Operating cash flow / net income1.28x
Accruals ratio11.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $42.17M | $26.39M | $257.24M | $211.04M | $326.55M |
| Cost of revenue | $13.81M | $8.73M | $158.99M | $70.08M | $57.59M |
| Gross profit | $28.36M | $17.66M | $98.25M | $140.96M | $268.96M |
| R&D expense | $108.89M | $91.83M | $109.44M | $199.36M | $363.11M |
| SG&A expense | $100.60M | $125.48M | $192.01M | $198.48M | $169.71M |
| Operating income | -$181.13M | -$199.65M | -$203.20M | -$256.88M | -$263.86M |
| Interest expense | $9.00M | $10.73M | $40.54M | $32.47M | $22.96M |
| Pretax income | -$183.12M | -$215.39M | -$238.27M | -$291.75M | -$287.10M |
| Income tax | $0 | $0 | -$380,000 | $0 | $0 |
| Net income | $168.02M | $28.51M | -$237.89M | -$291.75M | -$287.10M |
| EBITDA | -$179.83M | -$198.05M | -$200.00M | -$253.28M | -$260.36M |
| EPS (basic) | 1.43 | 0.25 | -2.53 | -3.76 | -3.81 |
| EPS (diluted) | 1.43 | 0.25 | -2.53 | -3.76 | -3.81 |
| Weighted avg. shares (diluted) | 117.14M | 114.55M | 94.16M | 77.63M | 75.45M |
| Balance sheet | |||||
| Cash & equivalents | $88.88M | $126.25M | $103.34M | $63.55M | $417.19M |
| Short-term investments | $83.25M | — | $14.86M | $128.13M | — |
| Receivables | $17.82M | $111.32M | $260.52M | $109.96M | $123.02M |
| Inventory | $3.17M | $4.21M | $62.60M | $38.79M | $37.64M |
| Current assets | $206.71M | $341.58M | $475.63M | $381.23M | $602.32M |
| PP&E, net | $1.34M | $2.58M | $5.12M | $8.75M | $7.81M |
| Goodwill | — | — | $943,000 | $943,000 | $900,000 |
| Intangibles | $20.00M | $24.79M | $41.87M | $5.93M | $3.56M |
| Total assets | $258.34M | $448.53M | $629.60M | $480.85M | $679.33M |
| Current liabilities | $140.39M | $282.98M | $331.77M | $138.69M | $165.33M |
| Total liabilities | $197.33M | $580.52M | $823.03M | $618.26M | $581.61M |
| Shareholders' equity | $61.01M | -$131.99M | -$193.43M | -$137.42M | $97.73M |
| Shares outstanding | 121.15M | 115.61M | 112.22M | 78.85M | 76.93M |
| Cash flow statement | |||||
| Operating cash flow | -$138.51M | -$20.44M | -$174.88M | -$241.12M | -$37.43M |
| Capital expenditure | — | — | $286,000 | $2.04M | $1.29M |
| Free cash flow | — | — | -$175.17M | -$243.16M | -$38.72M |
| Investing cash flow | $375.09M | $230.32M | $144.64M | -$166.85M | -$138.41M |
| Financing cash flow | -$273.70M | -$186.97M | $69.60M | $54.33M | $51.88M |
| Depreciation & amortization | $1.30M | $1.60M | $3.20M | $3.60M | $3.50M |
| Stock-based compensation | $16.97M | $27.80M | $43.11M | $50.74M | $51.36M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.